Welcome to our dedicated page for Senti Biosciences Holdings news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences Holdings stock.
Senti Biosciences Holdings, Inc. (SNTI) operates through Senti Bio as a clinical-stage biotechnology company developing cell and gene therapies built on a proprietary Gene Circuit synthetic biology platform. The company’s Gene Circuits are designed to program cells to sense, compute and respond to cellular environments, with applications intended to kill cancer cells, spare healthy cells, improve tissue specificity and allow post-administration control.
Recurring SNTI news centers on the Logic-Gated SENTI-202 program, an off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in relapsed or refractory acute myeloid leukemia. Company updates also cover clinical and translational data presentations, peer-reviewed research on NOT-gated CAR circuits in T cells and NK cells, FDA designations for SENTI-202, financial results, conference appearances, and partnership discussions tied to the Gene Circuit platform.
Senti Biosciences Holdings (NASDAQ:SNTI) announced a strategic transaction under which a new privately held biotechnology company controlled by affiliates of its largest investor, Celadon, will acquire SBH’s Gene-Circuit-enabled pipeline assets, including rights to SENTI-202. In return, SBH equity holders will receive a contingent value right (CVR) tied to potential future milestone payments of up to $60 million over seven years, triggered by SENTI-202 development, regulatory and commercial achievements.
SBH will retain and focus on next-generation controllable genetic medicines based on its Regulator Dial™ platform, including a controllable gene therapy for Rett syndrome and controllable armored TILs for solid tumors. SENTI-202 has FDA RMAT designation and showed durable MRD-negative responses in a 22-patient Phase 1 AML trial, with a donor characteristic identified for future allogeneic manufacturing. The deal is approved by SBH’s board and remains subject to stockholder and other customary approvals.
Summary not available.
Senti Biosciences (Nasdaq:SNTI) reported first quarter 2026 results and key SENTI-202 milestones. Cash was $8.9 million on March 31, 2026, versus $16.4 million year-end 2025. Net loss narrowed to $4.2 million from $14.1 million, with operating cash use falling to $7.5 million from $14.1 million.
The company finalized a pivotal single-arm, multi-center SENTI-202 trial design in R/R AML after a positive FDA RMAT meeting and reported durable MRD-negative responses in a 22-patient Phase 1 study. A new Donor X manufacturing attribute showed 50% cCR (7/14) in treated patients.
Senti Bio also arranged up to $40 million in senior secured convertible notes plus potential $60 million in contingent value rights and recorded a $6.9 million lease-modification gain from restructuring actions that reduced future lease obligations and operating expenses.
Senti Biosciences (Nasdaq:SNTI) reported a positive FDA RMAT Type B meeting for SENTI-202 in relapsed/refractory AML and finalized a single-arm, multi-center registrational trial and CMC strategy.
Phase 1 data showed higher responses with Donor X NK cells, durable MRD-negative remissions, and supportive preclinical survival results.
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the AACR Annual Meeting 2026 on April 17, 2026, in San Diego. The educational session, “Engineered NK Cells: From Innate Immunity to Clinical Innovation,” will highlight advances in Senti’s logic-gated SENTI-202 cell therapy and recent clinical trial results in relapsed/refractory acute myeloid leukemia.
The presentation will run 3:00–4:30 PM PT and will discuss how Logic Gates aim to increase therapeutic windows and improve precision in oncology cell therapies.
Senti Biosciences (Nasdaq: SNTI) announced a Cell Systems publication (April 1, 2026) describing a systematic framework for NOT-gated CAR circuits in T and NK cells. The study tested more than 60 CAR circuit designs, identified LIR1-based inhibitory CARs as potent regulators, and showed selective tumor killing with reduced exhaustion and preserved cytotoxicity in vitro and in vivo, supporting portability across CAR T and CAR NK modalities and the Gene Circuit platform. A patent application covering aspects of the technology has been filed.
Senti Biosciences (Nasdaq: SNTI) reported fourth-quarter and full-year 2025 results and a corporate update on March 27, 2026. Key highlights: RMAT designation for SENTI-202 in relapsed/refractory AML, updated positive preliminary Phase 1 data for SENTI-202, and continued Gene Circuit platform progress.
Financials: $16.4M cash at Dec 31, 2025; Q4 R&D $7.8M; FY2025 R&D $37.6M; Q4 G&A $5.8M; FY2025 G&A $26.2M; Q4 net loss $14.5M ($0.53/share); FY net loss $61.4M ($2.73/share) including a $5.1M impairment and $5.7M stock‑based comp.
Senti Biosciences (Nasdaq: SNTI) will present clinical and translational data for SENTI-202 at the 11th Annual Innate Killer Conference, March 24–25, 2026 in San Diego. Presentations cover Phase I safety and preliminary anti-leukemic activity, correlative analyses supporting the logic-gated mechanism, and a biomarker workshop.
Senti Biosciences (Nasdaq: SNTI) announced that CEO and co-founder Timothy Lu, M.D., Ph.D. will present at the Leerink Partners 2026 Global Healthcare Conference in Miami on March 9, 2026 at 2:20 PM ET. A live webcast will be available and a replay will be posted on the company’s Investors Events page.
This is a corporate presentation by a clinical-stage company developing cell and gene therapies using its Gene Circuit platform.
Senti Biosciences (Nasdaq: SNTI) announced that CEO Timothy Lu will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, 3:10–3:40 PM ET. The presentation will cover the Gene Circuit platform, pipeline progress, and partnership opportunities. Live audio and video webcasts will be available on the company website.